Galcanezumab Completed Phase 3 Trials for Chronic Migraine Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02614261Evaluation of Galcanezumab in the Prevention of Chronic Migraine